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Dietary fatty acids (FA) are the major determinants of blood lipids, and measurements of plasma phospholipid FA (PL-FA) composition that reflect
the dietary intake of FA may provide insights into the relationships between diet and CHD. We assessed CHD mortality associations with PL-FA
(SFA, PUFA and MUFA) levels measured in a nested case–control study of 116 cases of CHD death and 239 controls that were frequency-
matched for age and employment grade. The participants had plasma levels of total cholesterol, LDL-cholesterol (LDL-C), HDL-cholesterol,
apo B and apo A1, C-reactive protein (CRP) and fibrinogen recorded. SFA levels were significantly positively correlated with total cholesterol,
LDL-C, apo B, CRP protein and fibrinogen. By contrast, phospholipid-PUFA were inversely associated with CRP, but not with any of the
lipids. A higher SFA content (top v. bottom quarter) was associated with a 2-fold higher risk of CHD (OR and 95% CI: OR 2·12; 95% CI:
1·13, 3·99), and an equivalent difference in PUFA was associated with a halving in CHD risk (OR 0·49; 95% CI: 0·26, 0·94), but MUFA was
unrelated to CHD risk. These associations were substantially attenuated, after additional adjustment for lipids and inflammatory markers.
Higher levels of saturated fat and lower levels of polyunsaturated fats were each associated with a higher risk of CHD in elderly men, and
these associations were partly explained by their effects on blood lipids and biomarkers of inflammation.
Saturated fat: Polyunsaturated fat: Monounsaturated fat: Heart disease mortality: Elderly: Nested case–control studies
Much of our knowledge about the importance of dietary fats
for the prevention of CHD has been derived from the meta-
bolic ward studies, which assessed the effects of varying
intakes of dietary fatty acids (FA) on plasma levels of total
cholesterol and its fractions (LDL-cholesterol (LDL-C) and
HDL-cholesterol (HDL-C))(1,2). Since the dietary intake of
FA is difficult to assess reliably in free-living populations, it
is likely that observational epidemiological studies relating
the dietary intake of FA in individuals may have underesti-
mated the importance of FA for CHD risk(3,4). Plasma phos-
pholipid FA (PL-FA) proportions are a valid marker of cell
membrane FA proportions that is closely correlated with the
intake of dietary FA and can be measured directly(5,6).
Hence, the measurements of PL-FA proportions may provide
useful insights into the relationships between diet and CHD
risk. In a 6·8-year follow-up of cohort study of older men
who were free of CHD, stroke or statin use at baseline, we
examined the strength of the associations between plasma
PL-FA proportions and (i) plasma lipids (total, LDL-C and
HDL-C, and apo B and apo A1); (ii) inflammatory biomarkers
(C-reactive protein (CRP), albumin and fibrinogen); (iii) sub-
sequent risk of death from CHD.
Methods
Study population
Male civil servants working in London and aged 40–69 years
(n 19 019) were recruited between 1967 and 1970 into the
Whitehall study, details of which have been reported pre-
viously(7,8). Following the success of a pilot study of the feasi-
bility of recontacting participants in 1995, all 8448 surviving
participants were sought for resurvey during 1997–
1998(9,10). A postal questionnaire asked details of diagnoses
(e.g. ever told by a doctor that they had angina, heart attack
or diabetes), medications taken in the last month, smoking
status and the last known civil service employment grade(10).
The 7044 participants who responded to the resurvey (83%)
were subsequently sent a blood collection kit and asked to
attend their local surgery to have a blood sample collected,
blood pressure measured, and height and weight recorded.
Non-fasting blood samples were obtained from 5434 men
(77% of the respondents). Medical history, medication use
and mortality follow-up status (see later) were available for
5360 of these men (98·6%). The resurvey was approved by
the ethics committees of the participating institutions.
*Corresponding author: Dr Robert Clarke, fax þ44 1865 743985, email robert.clarke@ctsu.ox.ac.uk
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Mortality follow-up and design of the nested case–control study
The participants who died before October 2005 were identified
at the Office for National Statistics, which provided the date
and cause of all deaths (including International Classification
of Disease (ICD) codes). The mean follow-up period was
6·8 years (maximum 8·4 years). Cause-specific mortality was
coded using ICD-9 up to August 2002 and ICD-10 sub-
sequently. CHD deaths were pre-defined as those allocated
ICD-9 codes 410–414 and ICD-10 codes I20–I25 as the
underlying cause of death. All CHD deaths among individuals
with no prior history of heart attack, angina or stroke or use of
statins and available plasma were selected as cases. From the
remaining men with no prior history of CVD or use of statins,
two controls were selected for each case and were frequency-
matched to obtain the same 5-year age group by employment
grade distribution as that of the cases. A total of 122 cases and
244 controls were selected from which the PL-FA results were
available on 116 incident cases and 239 controls.
Laboratory methods
Blood was collected into a 10ml vacutainer containing
potassium EDTA with 0·34mmol/l aprotinin. These whole-
blood samples were mailed in sealed transport tubes at room
temperature to the laboratory inOxford. Themean time in transit
was 1·3 d (range 0–7 d), with 78% arrivingwithin 24 h and 96%
arriving within 48 h of blood collection. On arrival in the labora-
tory, the bloodwas centrifuged, and the plasmawas aliquoted for
storage at 2408C. All lipid analyses were performed on Beck-
man Synchron CX4 and CX5 auto-analysers (Beckman Coulter
UK Limited, High Wycombe, England, UK), which were pro-
grammed to subtract a sample blank absorbance reading from
the final reaction absorbance to correct for any interference
from haemolysis. The total cholesterol was measured enzymati-
cally using Beckman reagent and HDL-C was measured
directly using N-geneous reagents (Bio-Stat Limited, Stockport,
England, UK). Details of the methods used to measure the other
lipid indices (apoA1, apo B and directly measured LDL-C) have
been previously published(6). The intra-assay coefficients of
variation, based on repeat assays of laboratory control material,
were 4% for apo A1 and apo B, 5% for HDL-C and LDL-C, and
2% for total cholesterol. Previous studies had indicated that
minor changes in blood lipids arose due to delayed separation
of mailed blood samples, so blood lipid values were adjusted
for the time spent in transit(11,12), and also for the date of assay
to avoid assay drift. Blood lipids were available in 348 out of a
total of 355 men with PL-FA results.
Plasma phospholipid fatty acids
Plasma lipids were extracted withmethanol, methylene chloride
and saline (1:5:10:15) as previously described(13). The lipid
fraction was removed, the solvent evaporated under nitrogen
and resuspended in 1·5ml of chloroform. The phospholipid
fraction was isolated by solid-phase extraction after first remov-
ing the neutral lipids and NEFA. Once isolated, the phospholi-
pids were heated with boron trifluoride (14%) in methanol for
10min at 1008C to generate FA methyl esters. These were
extracted with hexane and water, and then analysed by GC
with flame ionisation detection. The GC analysis was carried
out with an Agilent 6890 (Agilent Technologies, Palo Alto,
CA, USA) equipped with a capillary column (SP2560, 100m,
Supelco, Bellefonte, PA, USA). The column conditions were
as follows: initial temperature, 2008C for 1·8min; ramp from
198C/min to 2408C; hold to 16min; carrier gas, hydrogen.
A mixture of FA (GLC 673b, Nuchek Prep, Elysian, MN,
USA) was included with each run as an external standard for
peak identification and response factor adjustment. The
response factor for palmitic acid was assumed to be 1·0, and
that, for all other FA, the response factor was calculated based
on this assumption. The FA peak areas were adjusted on a
daily basis using these response factors, and adjusted area per
cents were calculated. The coefficients of variation for PL-FA
composition for SFA, PUFA and MUFA, as well as for total
n-6 and n-3 FA, were 5% or less. Among the 355 participants,
the mean time in post for blood samples before the separation
of plasma from whole blood was 1 d or less for 273 (77%),
2 d for 61 (17%), 3 d for 13 (4%), 4 d for 3 (1%) and 5 d for 5
(1%), and no attempt was made to correct for days in post on
FA proportions.
Statistical methods
Spearman’s correlation coefficients were used to examine the
associations between PL-FA and plasma levels of lipids and
inflammatory biomarkers in all participants using stored blood
samples collected at enrolment in both controls and cases.
The ANOVA was used to assess the associations of plasma
lipids with individual PL-FA and various PL-FA classes. The
logistic regression was used to estimate OR (and 95% CI) of
CHD mortality for quartiles of PL-FA among controls after
adjustment for the matching factors, age and civil service
employment grade. These analyses were repeated with further
adjustment for smoking habit, diabetes, treatment for high
blood pressure, BMI, systolic blood pressure, apo A1, HDL-C,
apo B and LDL-C, CRP, albumin and fibrinogen. The stepwise
change in the x 2 statistic after making these adjustments pro-
vided a quantitative indication of potential confounding effects
of these factors(14). In order to preserve all participants in the
analyses, multiple imputations were used to generate five data-
sets containing imputed data in place of the missing values(15).
The analyses conducted on each of these datasets gave very simi-
lar results and themean of these estimates is presented. The stan-
dard errors for thesemeans are computed as the average standard
error across the five datasets plus a term that allows for the vari-
ation in the estimates across the five analyses. All analyses were
carried out using Statistical Analysis Systems version 8.1 (SAS
Institute, Cary, NC, USA).
Results
Characteristics of the study participants
The mean age of cases was 79·2 (SD 4·5) years, and cases
and controls were well matched for age, employment grade,
smoking, blood pressure, BMI and diabetes mellitus. Approxi-
mately 40% of the cases and 30% of the controls gave a his-
tory of hypertension. The majority of men were non-smokers,
mean blood pressure was 145/80mmHg and mean BMI
was 24·8 kg/m2. Over 90% of men had achieved a high
socio-economic class (as determined by the last known
employment grade).
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Case–control differences
Table 1 shows the distribution of proportions of PL-FA
markers at enrolment in men who subsequently died of
CHD (cases) compared with survivors during the follow-up
(controls). Among PL-FA in controls, PL-SFA accounted for
43·5%, polyunsaturated accounted for 40·4%, monounsatu-
rated accounted for 15·6% and trans-FA accounted for less
than 0·5% of the total PL-FA. CHD cases had higher levels
of stearic acid and lower levels of total PUFA and n-6 FA ara-
chidonate when compared with controls, but, otherwise, the
case–control differences in the FA distributions at enrolment
were not statistically significant.
Associations with blood lipids, inflammatory biomarkers
and BMI
Table 2 shows the mean plasma levels of blood lipids, CRP and
BMI by quarters of the PL-FA. Individuals in the top compared
with the bottom quarter of the PL-SFA had higher levels of total
cholesterol, LDL-C and apo B and lower levels of HDL-C com-
pared with those in the bottom quarter of the PL-SFA. Table 2
also shows the Spearman correlation coefficients for the
plasma FA with plasma lipids and biomarkers of inflammation.
Among the 348 individuals with available data, PL-SFA were
positively correlated with apo B (r 0·15, P¼0·004), LDL-C
(r 0·16, P¼0·004) and total cholesterol (r 0·16, P¼0·003),
respectively. PL-SFA were also positively correlated with
CRP (r 0·12, P¼0·02) and fibrinogen (r 0·11, P¼0·05), but not
with albumin (r 0·07, P¼0·09). By contrast, phospholipid-
PUFA (PL-PUFA) was not significantly associated with any of
the lipids, but was inversely correlated with CRP (r 20·13,
P¼0·01). PL-SFA was inversely associated with PL-PUFA
(r 20·48, P,0·001), and to a lesser extent with PL-MUFA
(r 20·15, P,0·001).
Associations with IHD mortality
Higher PL-SFA was positively associated with CHD mortality
and higher PL-PUFA was inversely associated with CHD
Table 1. Plasma phospholipid fatty acid composition (%) in CHD cases and matched controls at enrolment
(Mean values and standard deviations)
CHD cases (n 116) Controls (n 239)
Mean SD Mean SD P value
History
Age (years) 79·2 4·5 78·8 4·9 0·44
Smoking, current smoker (%) 9·2 7·1 0·72
Hypertension (%) 38·8 28·9 0·06
Diabetes (%) 2·7 4·3 0·48
Employment grade, low (%) 6·9 63 0·94
Clinical
Systolic BP (mmHg) 148·6 23·0 144·9 19·9 0·15
Diastolic BP (mmHg) 80·3 11·5 79·8 10·5 0·71
BMI (kg/m2) 25·2 3·6 24·8 3·1 0·26
Laboratory
Total cholesterol (mmol/l) 5·68 1·01 5·49 1·03 0·10
LDL-cholesterol (mmol/l) 3·51 0·85 3·35 0·83 0·07
HDL-cholesterol (mmol/l) 1·09 0·40 1·10 0·36 0·94
apo B (g/l) 91·2 25·5 85·6 27·8 0·07
apo A1 (g/l) 95·8 18·5 93·7 13·9 0·29
CRP (mg/l) 2·32 1·03 1·55 1·09 ,0·001
Fibrinogen (g/l) 3·73 0·81 3·49 0·84 0·01
Albumin (g/l) 39·3 2·7 39·6 3·0 0·25
Saturated (%)
Palmitic acid (16 : 0) 29·3 1·6 29·1 1·3 0·27
Stearic acid (18 : 0) 14·5 1·6 14·2 1·6 0·05
All saturated 43·8 2·0 43·5 1·9 0·11
C18 trans (%)
Elaidic acid (18 : 1n-9 trans) 1·5 1·1 1·4 0·4 0·28
Linoelaidic (18 : 2n-6 trans, trans) 0·1 0·1 0·1 0·1 0·28
Monounsaturated (%)
Oleic acid (18 : 1n-9) 12·8 2·2 12·6 2·1 0·44
All monounsaturated 15·9 2·0 15·6 2·4 0·20
Polyunsaturated (%)
Linoleic acid (18 : 2n-6) 21·8 3·4 22·0 3·2 0·54
Arachidonic acid (20 : 4n-6) 7·2 1·3 7·5 1·4 0·04
Eicosapentaenoic acid (20 : 5n-3) 1·5 1·0 1·5 0·8 0·99
n6-Docosapentaenoic (22 : 5n-6) 0·1 0·1 0·1 0·1 0·85
n3-Docosapentaenoic (22 : 5n-3) 1·1 0·3 1·2 0·2 0·07
DHA (22 : 6n-3) 4·4 1·3 4·5 1·4 0·32
Total n-3 7·6 2·2 7·7 2·1 0·51
Total n-6 32·2 3·4 32·7 3·2 0·13
All polyunsaturated 39·7 3·0 40·4 2·0 0·02
BP, blood pressure.
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mortality, but PL-MUFA was not associated with CHD mor-
tality (Table 3). Specifically, men with PL-SFA in the top
quarter had a 2-fold higher risk of CHD (OR 2·12; 95% CI:
1·13, 3·99), compared with men in the bottom quarter, after
adjustment for age and employment grade. For PL-PUFA,
men in the top compared with the bottom quarter had a
2-fold lower risk of CHD mortality (OR 0·49; 95% CI:
0·26, 0·94), after adjustment for age and grade. By contrast,
the differences in PL-MUFA were unrelated to the risk of
CHD. The associations with CHD risk for either PL-SFA or
PL-PUFA were only slightly attenuated after adjustment for
smoking, systolic blood pressure, diabetes and employment
grade, but were no longer significant after additional adjust-
ment for lipids and inflammatory biomarkers, respectively.
After making these adjustments, the stepwise reductions by
almost 50% in the x 2 statistic for PL-SFA and CHD from
5·4 to 2·6 and for PL-PUFA from 4·9 to 2·9 provided a quan-
titative indication of potential confounding effects of these
factors. These reductions indicate that almost half of the
effects of PL-SFA and PL-PUFA were explained through
their effects on blood lipids and inflammatory markers.
Discussion
Elderly men with plasma SFA in the top quarter of the popu-
lation distribution had twice the risk of dying from CHD com-
pared with those in the bottom quarter, and men with higher
plasma levels of PUFA in the top quarter were half as likely
to die from CHD compared with those in the bottom quarter.
This suggests that even at 70 and 80 years of age, FA pro-
portions appear to influence the cardiovascular health. The
results of the present study differ from the previous studies
linking FA proportions to CHD risk, in that the present
study allowed for adjustment of risk with lipids and bio-
markers of inflammation. As such, the study could address
the extent to which the link between PL-FA and risk was
mediated by known risk factors for CHD. The substantial
attenuation in the risk of CHD death in the multivariate
model, which included lipids and lipoproteins and biomarkers
of inflammation when compared with the simpler age-class
model which did not, suggests that the adverse effects of
PL-SFA and the beneficial effects of PL-PUFA are partly
mediated by the traditional CHD risk factors.
The present study is consistent with previous reports(16,17)
from other studies that reported protective effects of higher
levels of PUFA on the prospective risk of CVD; however, it
was not consistent with several other studies in which higher
PUFA biomarkers were not independently associated with
CHD risk(18–20). The precise reasons for the discrepant find-
ings of different studies of the same topic remain unclear,
but may reflect the differences in the distribution of PUFA,
prevalent disease or incomplete adjustment for the effects of
other CVD risk factors. In the large US Nurses Health study
involving 939 CHD events during a 14-year period among
80 082 middle-aged women, a higher intake of SFA was
associated with increased IHD risk and a higher intake
of unsaturated fat (PUFA and MUFA) was associated with a
lower IHD risk(2). The discrepancy between the studies of
dietary intake of unsaturated FA compared with those of
blood markers of such FA may reflect the poor correlation
of dietary intake with blood markers. The replacement of
SFA by either PUFA or MUFA was associated with a further
reduction in CHD, but the substitution of SFA by carbohydrate
was associated with only small and non-significant differences
in the risk of CHD(2). The results of the present study based on
the plasma PL-FA levels are generally consistent with these
Table 2. Age-adjusted mean values of blood lipids and other risk factors by quarters of plasma fatty acids and associated correlation coefficients
Quarters of fatty acids
Plasma fatty acid
mean (%)
apo B
(g/l)
apo A1
(g/l)
Total cholesterol
(mmol/l)
HDL-C
(mmol/l)
LDL-C
(mmol/l)
CRP*
(mg/l)
BMI
(kg/m2)
Number of subjects 348 348 348 348 348 348 330
Saturated fat
I (lowest) 41·5 0·80 0·93 5·28 1·12 3·21 1·65 24·1
II 42·8 0·87 0·95 5·54 1·10 3·39 1·45 25·0
III 43·9 0·87 0·94 5·52 1·07 3·39 1·98 25·5
IV (highest) 46·1 0·90 0·95 5·79 1·10 3·59 2·07 25·1
Difference (IV 2 I) 4·6 0·10 0·02 0·51 20·02 0·38 0·42 1·0
Spearman’s correlation 0·15 0·02 0·16 20·07 0·16 0·12 0·13
P value 0·004 0·73 0·003 0·20 0·004 0·02 0·02
Monounsaturated fat
I (lowest) 12·8 0·88 0·94 5·62 1·08 3·45 1·62 24·9
II 14·9 0·83 0·97 5·55 1·18 3·43 1·46 24·5
III 16·3 0·86 0·92 5·45 1·05 3·35 2·05 24·9
IV (highest) 18·8 0·87 0·95 5·51 1·08 3·36 2·01 25·4
Difference (IV2 I) 6·0 20·01 0·01 20·11 0·00 20·09 0·39 0·5
Spearman’s correlation 20·02 20·06 20·05 20·05 20·04 0·09 0·04
P value 0·72 0·30 0·37 0·40 0·45 0·11 0·46
Polyunsaturated fat
I (lowest) 36·5 0·92 0·95 5·72 1·08 3·52 2·12 25·6
II 39·5 0·83 0·94 5·34 1·09 3·29 2·04 25·0
III 41·3 0·84 0·94 5·51 1·09 3·38 1·50 24·8
IV (highest) 43·4 0·86 0·95 5·55 1·13 3·39 1·51 24·3
Difference (IV2 I) 6·9 20·06 0·00 20·17 0·05 20·13 20·61 21·3
Spearman’s correlation 20·07 0·03 20·05 0·07 20·07 20·13 20·11
P value 0·17 0·55 0·32 0·18 0·22 0·01 0·04
* Geometric means presented.
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findings and suggest that replacing SFA by either MUFA or
preferably PUFA is likely to be a cardioprotective dietary
strategy(2). However, it must be recognised that neither PL-
SFA nor PL-MUFA necessarily reflect the dietary intake
since both of these classes of FA can be synthesised de novo;
PL-PUFA, on the other hand, is reflective of PUFA intakes.
While the proportions of PUFA may be influenced by the pre-
sence of diabetes or glucose intolerance, it was not possible to
exclude the effects of undiagnosed diabetes on the PUFA
levels in this population.
In contrast to other studies, there was no relationship between
the PL n-3 PUFA levels and the risk of CHD death. It is possible
that the prospective matching on employment grade (a surrogate
for the socio-economic status) may have contributed to this
failure. In addition, it must be appreciated that the subjects in
this study may have been unusually resistant to CHD, being a
mean age of seventy-nine at entry and having no history of
CHD, hypercholesterolaemia or statin use. Arachidonic acid
levels were lower in cases than in controls. This observation
does not support the view that arachidonic acid is pro-atherogenic
(since it serves as the substrate for the synthesis of pro-inflamma-
tory eicosanoids), but is consistent with a recent meta-analysis(21)
showing no increase in the risk of CHD events associated with
higher arachidonic acid levels.
The results of the present study support expert recommen-
dations in the UK, where there has been a shift in dietary
advice away from reducing the total fat intake (and replacing
with carbohydrate) towards replacing SFA by PUFA and
MUFA(17,22,23). In addition, higher intakes of n-3 FA from
fish are recommended, with a target of approximately
450mg/d. Several large-scale trials are presently underway,
assessing the effects on the vascular risk of higher intake of
PUFA and the results of these trials are now required to
assess the independent relevance of n-3 FA and n-6 FA for
vascular and non-vascular mortality.
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